A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.

Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment ...

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths ...

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural ...

Bob Lane discusses his experience with prostate cancer, and describes what survivorship and cure means to him as someone ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and ...

Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during ...